RAINBOW: Adverse reaction profile for CYRAMZA in combination with paclitaxel¹,²

RAINBOW: ADVERSE REACTIONS OCCURRING AT INCIDENCE RATE ≥ 5% AND A ≥ 2% DIFFERENCE BETWEEN ARMS IN PATIENTS RECEIVING CYRAMZA IN COMBINATION WITH PACLITAXEL1

CYRAMZA in combination with paclitaxel adverse reactions chart
  • The incidence of febrile neutropenia was 2.4% vs 1.2% in the CYRAMZA plus paclitaxel and placebo plus paclitaxel treatment arms, respectively1,2
  • 19% of patients treated with CYRAMZA plus paclitaxel received granulocyte colony-stimulating factors vs 8.5% of patients treated with paclitaxel1,3
  • In the RAINBOW trial, 28% of patients in the CYRAMZA plus paclitaxel treatment arm received CYRAMZA for at least 6 months1
    • In the CYRAMZA plus paclitaxel treatment arm, the median duration of exposure to CYRAMZA was 18 weeks and to paclitaxel was 17.7 weeks. In the placebo plus paclitaxel treatment arm, the median duration of exposure was 12 weeks for each1,4

Select Important Safety Information

  • The most common serious adverse events with CYRAMZA plus paclitaxel in study 2 were neutropenia (3.7%) and febrile neutropenia (2.4%); 19% of patients treated with CYRAMZA plus paclitaxel received granulocyte colony-stimulating factors.
  • Adverse reactions resulting in discontinuation of any component of the CYRAMZA plus paclitaxel combination in 2% or more patients in study 2 were neutropenia (4%) and thrombocytopenia (3%).
  • Clinically relevant adverse reactions reported in ≥ 1% and 5% of the CYRAMZA plus paclitaxel-treated patients in study 2 were sepsis (3.1% for CYRAMZA plus paclitaxel vs 1.8% for placebo plus paclitaxel) and gastrointestinal perforations (1.2% for CYRAMZA plus paclitaxel vs 0.3% for placebo plus paclitaxel).

RAINBOW: Additional adverse reactions to consider for CYRAMZA as an antiangiogenic therapy1,5

RAINBOW: ADDITIONAL ADVERSE REACTIONS1,5
Additional adverse reactions for CYRAMZA monotherapy

Impaired Wound Healing

  • Impaired wound healing can occur with antibodies inhibiting the VEGF pathway. CYRAMZA has not been studied in patients with serious or nonhealing wounds. CYRAMZA, an antiangiogenic therapy, has the potential to adversely affect wound healing. Withhold CYRAMZA prior to surgery. Resume CYRAMZA following the surgical intervention based on clinical judgment of adequate wound healing. If a patient develops wound healing complications during therapy, discontinue CYRAMZA until the wound is fully healed.
References:
  1. CYRAMZA (ramucirumab) [package insert]. India, Eli Lilly & Company (India) Pvt. Ltd.
  2. Data on file, Eli Lilly and Company. ONC09302014c.
  3. Data on file, Eli Lilly and Company. ONC09302014d.
  4. Data on file, Eli Lilly and Company. ONC20141014b.
  5. Data on file, Eli Lilly and Company. ONC09302014e.
Top